Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Overview of the Vascular System

Overview of the Vascular System

The vascular system comprises an extensive network of arteries, capillaries, and veins. The vascular system can be broadly divided into the blood and lymphatic systems. Typically, blood vessels can be categorized into three histological regions: tunica intima, tunica media, and tunica adventitia. The tunica intima consists of a single layer of endothelial cells attached to the basal lamina. Underlying the basal lamina is a connective tissue layer and an elastic lamina that gives stability and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Same author

Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States.

Pediatric blood & cancer·2025

Same author

Hypoalbuminemia and Nutritional Status in Children With Cancer.

Pediatric blood & cancer·2024

Same author

Designing Patient-Reported Measures of Fertility: Cognitive Interview Findings from Adolescents and Young Adults with Cancer.

Journal of adolescent and young adult oncology·2024

Same author

Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study.

Pediatric blood & cancer·2023

Same author

Practice Variations in Managing Infantile Hemangiomas.

Journal of pediatric hematology/oncology·2023

Search research articles

Related Experiment Video

Updated: Oct 8, 2025

A Patient-Derived Xenograft Model for Venous Malformation

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

Infantile Hemangioma: A Current Review.

Kristy S Pahl¹, Thomas W McLean²

¹Department of Pediatrics, Duke University School of Medicine, Durham.

Journal of Pediatric Hematology/Oncology

|December 30, 2021

Summary

Infantile hemangiomas (IHs) are common benign vascular tumors in infants. Propranolol and other beta-blockers are now the standard, safe, and effective treatment, dramatically improving outcomes.

More Related Videos

A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay

A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay

Published on: April 12, 2018

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

Related Experiment Videos

Last Updated: Oct 8, 2025

A Patient-Derived Xenograft Model for Venous Malformation

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay

A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay

Published on: April 12, 2018

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

Area of Science:

Pediatric Dermatology
Vascular Biology
Clinical Therapeutics

Background:

Infantile hemangiomas (IHs) are common benign vascular tumors in infants, potentially causing functional and cosmetic issues.
The discovery of propranolol's efficacy over a decade ago revolutionized IH treatment and prognosis.
Accurate diagnosis is critical as IH can mimic other lesions or indicate underlying syndromes.

Purpose of the Study:

To review the current understanding and management of infantile hemangiomas.
To highlight the impact of propranolol and other beta-blockers on IH therapy.
To emphasize the importance of early diagnosis and treatment initiation.

Main Methods:

Review of recent clinical studies and therapeutic guidelines for infantile hemangiomas.
Analysis of the efficacy and safety of oral propranolol, other beta-blockers, and topical timolol.
Discussion of diagnostic challenges and the significance of IH as a potential syndromic manifestation.

Main Results:

Oral propranolol and other beta-blockers, along with topical timolol, are established as safe and effective first-line treatments for IH.
These therapies have largely replaced previous treatment modalities due to improved outcomes.
Early treatment initiation is crucial for optimizing therapeutic success in IH management.

Conclusions:

Current therapeutic strategies for infantile hemangiomas, particularly beta-blocker therapy, have significantly improved patient prognosis.
Prompt recognition, accurate diagnosis, and timely referral are essential for effective management.
Ongoing research in both basic science and clinical aspects promises further advancements in IH care.